Status:
COMPLETED
COVID-19 Study at the Russian Clinical and Research Center of Gerontology of the Pirogov RNRMU
Lead Sponsor:
Pirogov Russian National Research Medical University
Collaborating Sponsors:
City Clinical Hospital No.52 of Moscow Healthcare Department
Conditions:
COVID-19
Mild to Moderate
Eligibility:
All Genders
18+ years
Brief Summary
This is a retrospective observational cohort study. About 1000 hospital charts of adult patients admitted to the hospital with mild-to-moderate COVID-19 from February to August 2020 were analyzed to e...
Detailed Description
The clinical data from 154 patients were retrospectively collected according to Inclusion and Exclusion criteria. Finally all patients were divided into four groups depending on therapy: 38 patients w...
Eligibility Criteria
Inclusion
- Subjects who meet all of the following criteria were included in the study:
- Patients were hospitalized in two Moscow specialized COVID-19 care units from 02/01/2020 to 08/31/2020.
- Patients had symptoms of acute respiratory infection (fever, muscle pain, cough) and radiologically-defined viral pneumonia as assessed by computed tomography
- All patients written informed consent for 'off-label' drug use for persons who received tocilizumab, netakimab, or baricitinib
Exclusion
- Subjects who meet any of the following criteria were excluded from participation in the study:
- Pregnant women
- Patients with unknown National Early Warning Score 2 (NEWS2) metric or with NEWS2 \> 6 points on the first day of therapy
- Patients with the plasma level of CRP \> 140 mg/l on the first day of therapy
- Information about the outcome of patients (death or discharge from the hospital) was absent
- Patients who first time got the investigational drug later than 72 hours after hospitalization
- Patients who received a combination of the investigational drugs or application was differed to study design
- Patients with severe hematological, renal, or liver function impairment or evidence of concomitant bacterial infections.
Key Trial Info
Start Date :
February 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 30 2021
Estimated Enrollment :
154 Patients enrolled
Trial Details
Trial ID
NCT05302947
Start Date
February 1 2020
End Date
June 30 2021
Last Update
April 8 2022
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
City Clinical Hospital No. 52 of the Department of Health of the City of Moscow
Moscow, Russia, 123182
2
Pirogov Russian National Research Medical University
Moscow, Russia